These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38319500)

  • 1. Pathological response and tumor stroma immunogenic features predict long-term survival in non-small cell lung cancer after neoadjuvant chemotherapy.
    Wang S; Sun X; Dong J; Liu L; Zhao H; Li R; Yang Z; Cheng N; Wang Y; Fu L; Yi H; Lv Z; Huo H; Jin D; Mao Y; Yang L
    Cell Oncol (Dordr); 2024 Jun; 47(3):1005-1024. PubMed ID: 38319500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
    Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
    J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
    Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
    Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agreement on Major Pathological Response in NSCLC Patients Receiving Neoadjuvant Chemotherapy.
    Weissferdt A; Pataer A; Vaporciyan AA; Correa AM; Sepesi B; Moran CA; Wistuba II; Roth JA; Shewale JB; Heymach JV; Kalhor N; Cascone T; Hofstetter WL; Lee JJ; Swisher SG
    Clin Lung Cancer; 2020 Jul; 21(4):341-348. PubMed ID: 32279936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
    Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
    Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy.
    Pataer A; Kalhor N; Correa AM; Raso MG; Erasmus JJ; Kim ES; Behrens C; Lee JJ; Roth JA; Stewart DJ; Vaporciyan AA; Wistuba II; Swisher SG;
    J Thorac Oncol; 2012 May; 7(5):825-32. PubMed ID: 22481232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment patterns and clinical outcomes of patients with resectable non-small cell lung cancer receiving neoadjuvant immunochemotherapy: A large-scale, multicenter, real-world study (NeoR-World).
    Yang Z; Wang S; Yang H; Jiang Y; Zhu L; Zheng B; Fu H; Ma J; Xie H; Wang Z; He H; Xia C; Li R; Xu J; Han J; Huang X; Li Y; Zhao B; Ni C; Xing H; Chen Y; Wang J; Jiang Y; Song Y; Mao Y; Chen C; Yao F; Zhang G; Hu J; Xue Q; Gao S; He J;
    J Thorac Cardiovasc Surg; 2024 Oct; 168(4):1245-1258.e17. PubMed ID: 38342430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study.
    Zhai W; Zhang C; Duan F; Xie J; Dai S; Lin Y; Yan Q; Rao B; Li L; Zhou Y; Zhao Z; Long H; Wang J
    Front Immunol; 2024; 15():1422717. PubMed ID: 39108262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes associated with neoadjuvant therapy for the treatment of resectable non-small cell lung cancer in real-world practice.
    Huang X; Pang G; Mao Z; Li B; Teng Z; Yang Y; Qiu Z; Chen X; Wang P
    Clin Respir J; 2024 May; 18(5):e13761. PubMed ID: 38693705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
    Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
    Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery.
    Hou Z; Zhao L; Zou L; Li B
    Adv Clin Exp Med; 2023 Aug; 32(8):847-853. PubMed ID: 36881364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
    Pataer A; Shao R; Correa AM; Behrens C; Roth JA; Vaporciyan AA; Wistuba II; Swisher SG
    Cancer Med; 2018 Jun; 7(6):2405-2414. PubMed ID: 29673125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
    Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
    Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer.
    Si J; Zhang P; Tian D; Wang X; Ma Y; Zhang J; Wang L; Yang Y
    World J Surg Oncol; 2017 Jan; 15(1):34. PubMed ID: 28129775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.
    William WN; Pataer A; Kalhor N; Correa AM; Rice DC; Wistuba II; Heymach J; Lee JJ; Kim ES; Munden R; Gold KA; Papadimitrakopoulou V; Swisher SG; Erasmus JJ;
    J Thorac Oncol; 2013 Feb; 8(2):222-8. PubMed ID: 23287849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC.
    Kim SH; Cho BC; Choi HJ; Chung KY; Kim DJ; Park MS; Kim SK; Chang J; Shin SJ; Sohn JH; Kim JH
    Lung Cancer; 2008 Jun; 60(3):393-400. PubMed ID: 18155802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy.
    Wang F; Yang H; Chen W; Ruan L; Jiang T; Cheng L; Jiang H; Fang M
    Curr Probl Cancer; 2024 Jun; 50():101098. PubMed ID: 38704949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features.
    Khorrami M; Jain P; Bera K; Alilou M; Thawani R; Patil P; Ahmad U; Murthy S; Stephans K; Fu P; Velcheti V; Madabhushi A
    Lung Cancer; 2019 Sep; 135():1-9. PubMed ID: 31446979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated With Survival in Complete Pathologic Response Non-Small Cell Lung Cancer.
    Martinez-Meehan D; Lutfi W; Dhupar R; Christie N; Baker N; Schuchert M; Luketich JD; Okusanya OT
    Clin Lung Cancer; 2020 Jul; 21(4):349-356. PubMed ID: 32299769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
    Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
    J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.